ADVA
20.5.2021 09:02:13 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its new compact, low-power edge demarcation solution, giving network operators an easy and cost-efficient route to 10Gbit/s Carrier Ethernet services. The ADVA FSP 150-XG108 Series meets the precise needs of mobile network operators (MNOs) aiming to deliver a faster and more responsive experience by rolling out 5G New Radio equipment at scale. The solution also enables enterprises to affordably extend bandwidth as they push data to the cloud and supports the cost-effective expansion of digitized cable networks. Featuring zero-touch provisioning and 5G timing capabilities, the ADVA FSP 150-XG108 Series is ideal for growing network capacity while reducing footprint, power and cost.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005061/en/
“Today’s MNOs need to be able to seize new revenue opportunities and grow capacity without worrying about increased energy consumption or rack space eating into profitability. That’s where our FSP 150-XG108 Series hits the sweet spot. It provides a quick and seamless way to deploy high-bandwidth Carrier Ethernet services without major cost,” said Christoph Glingener, CTO, ADVA. “Our FSP 150-XG108 Series is engineered for the practical challenges of meeting cloud and 5G demand. It consumes very little power and supports both 1Gbit/s and 10Gbit/s interface speeds in a 1RU footprint. What’s more, with its temperature-hardened design, our FSP 150-XG108 Series removes the need for expensive air-conditioning.”
The ADVA FSP 150-XG108 Series enables network operators to easily and affordably migrate from 1Gbit/s to 10Gbit/s MEF 3.0 services. Using proven and established OAM processes, it offers simple operation and network integration. With zero-touch provisioning, the ADVA FSP 150-XG108 Series removes the need for technically trained onsite staff and makes service activation quick and easy. Its compact design caters for space-restricted applications and its redundant power supply ensures high availability. The ADVA FSP 150-XG108 Series is also well prepared for emerging timing requirements with hardware-assisted BITS, PTP and SyncE synchronization.
“We’re providing the compact, robust and reliable demarcation that mobile, cable and enterprise networks require for massive 10Gbit/s rollout. Our FSP 150-XG108 Series is simple, efficient and highly scalable. With zero-touch provisioning, service activation becomes effortless. The FSP 150-XG108 Series also offers intuitive network control and service monitoring through the automated management of our Ensemble Controller and Ensemble Packet Director,” commented James Buchanan, GM, Edge Cloud, ADVA. “And, despite being optimized for cost-sensitive, high-bandwidth applications, our FSP 150-XG108 Series doesn’t compromise on performance or synchronization. It’s the perfect choice for empowering any network edge with 10Gbit/s demarcation and aggregation.”
Watch this product video for more information: https://youtu.be/pAcqPOtO5eI .
Additional details are also available in this Tech Cam interview: https://youtu.be/bdd-AqvgpBM .
Supporting slides can be viewed here: https://adva.li/fsp-150-xg108-series-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005061/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom